Compliance & Ethics

Bundesbank President Joachim Nagel indicated in a Le Monde interview that an ECB rate increase at the September 10, 2026 meeting is effectively priced in, with markets assigning a probability above 95 percent. He declined to give guidance beyond that meeting, citing volatile energy and financial markets. Compliance and risk teams should treat this as a signal of tightening monetary conditions, not as binding regulatory guidance, and should prepare for related market, liquidity, and policy-driven changes.

The Norway Financial Supervisory Authority (Finanstilsynet) has published a warning about TIBIPRO, an entity identified with Spain as its issuer jurisdiction and referencing a Spanish CNMV warning notice. Compliance teams should treat TIBIPRO as a potentially unauthorized or high-risk counterparty and screen for any exposure. The source record is brief, so details of the underlying conduct should be confirmed in the linked CNMV notice.

The Norway Financial Supervisory Authority has published a warning about atlasgroupag.com, a website linked to Switzerland. The source link points to the Swiss regulator FINMA's warning list, which suggests the entity was first flagged there. Compliance teams should treat the domain as high risk and update screening and fraud controls accordingly.

A warning concerning Standards Reliance and its website, standardsreliance.com, has been published, and the source metadata is inconsistent: the record lists Norway's Financial Supervisory Authority as the regulator, but the linked notice and issuer field point to the Swiss Financial Market Supervisory Authority (FINMA). Compliance teams should treat the entity as a high-risk, potentially unauthorized provider and confirm the originating regulator before relying on the record in controls or reports.

Bank of America failed to report more than $5 billion in suspicious transactions in a timely manner and allowed serious deficiencies in its anti-money laundering controls to persist for years, even after regulators ordered the bank to correct them, according to enforcement actions announced Tuesday by the U.S. Treasury Department.

CVS Pharmacy and related corporate entities have agreed to pay $315 million to resolve federal allegations that the pharmacy chain filled unlawful prescriptions for opioids and other controlled substances for more than a decade, then sought reimbursement for many of those prescriptions from Medicare and other federal healthcare programs.

The UK's Serious Fraud Office (SFO) has opened a direct line to its senior legal leadership for companies considering whether to report suspected fraud, bribery or corruption, responding to concerns raised by lawyers since the agency revised its corporate cooperation guidance last year.